Astra, led by boss Pascal Soriot (pictured), said it is accelerating its expansion in US with an investment that will create ...

The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

U.K.-based drug giant AstraZeneca will make what it calls its single-largest manufacturing investment in the world with a new ...

Baghdad (IraqiNews.com) – The Iraqi Ministry of Health mentioned on Sunday that the agreement with Sanofi, a French ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

Sanofi and partner AstraZeneca have received approval from the U.S. Food and Drug Administration for a manufacturing line for their preventive respiratory syncytial virus (RSV) therapy, the French ...

Sanofi, in collaboration with its partner AstraZeneca plc (NASDAQ:AZN), has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023.

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat estimates, reaching €13.44 billion, up 12.3%.

76% of patients in the Dupixent trial reached ≥75% improvement in eczema severity at 24 weeks. Sanofi has tripled Beyfortus production and doubled manufacturing sites since its 2023 launch. PPI ...